Elsevier

Life Sciences

Volume 64, Issue 25, 14 May 1999, Pages 2351-2358
Life Sciences

Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland

https://doi.org/10.1016/S0024-3205(99)00188-5Get rights and content

Abstract

A family of five subtypes of muscarinic acetylcholine receptors (mAChR) has been identified based on their molecular structures and second signal transduction pathways. In the present study, we examined the antagonist binding profiles of 9 muscarinic antagonists (atropine, 4-DAMP, pirenzepine, oxybutynin, tiquizium, timepidium, propiverine, darifenacin and zamifenacin) for human muscarinic acetylcholine receptor subtypes (m1, m2, m3, m4 and m5) produced by using a baculovirus infection system in Sf9 insect cells and rat tissue membrane preparations (heart and submandibular gland). In a scopolamine methyl chloride [N-methyl-3H]- ([3H]NMS) binding assay, pirenzepine and timepidium displayed the highest affinities for the m1 and m2 subtypes, respectively, and both zamifenacin and darifenacin had the highest affinities for the m3 subtype, although the selectivities among the five subtypes were less than 10-fold. Propiverine showed a slightly higher affinity for the m5 subtype, whereas none of the drugs used in this study was uniquely selective for the m4 subtype. The binding affinities of muscarinic antagonists for rat heart and submandibular gland strong correlated with those for human cloned m2 and m3 subtypes, respectively. These data suggest that [3H]NMS binding studies using rat heart and submandibular gland might be useful methods which predict the affinities of test drugs for human muscarinic M2 and M3 receptor subtypes.

Reference (42)

  • WessJ. et al.

    Life Sci.

    (1995)
  • CaulfieldM.P.

    Pharmacol. Ther.

    (1993)
  • MaedaA. et al.

    FEBS Lett.

    (1988)
  • EglenR.M. et al.

    Trends Pharmacol. Sci.

    (1994)
  • HammerR. et al.

    Life Sci.

    (1986)
  • PetersonG.L.

    Methods of enzymol.

    (1983)
  • BonnerT.I. et al.

    Neuron

    (1988)
  • SchudtC. et al.

    Euro. J. Pharmacol.

    (1988)
  • WallisR.M.

    Life Sci.

    (1995)
  • RinkenA. et al.

    Biochem. Pharmacol.

    (1994)
  • Van KoppenC.J. et al.

    J. Biol. Chem.

    (1990)
  • BarnesP.J.

    Life Sci.

    (1993)
  • WessJ.

    Trends Pharmacol. Sci.

    (1993)
  • MitchelsonF.

    Pharmac. Ther.

    (1988)
  • NathansonN.M.

    Annu. Rev. Neurosci.

    (1987)
  • KuboT. et al.

    Nature

    (1986)
  • PeraltaE.G. et al.

    EMBO J.

    (1987)
  • BonnerT. et al.

    Science

    (1987)
  • HulmeE.C. et al.

    Annu. Rev. Pharmacol. Toxicol.

    (1990)
  • HammerR. et al.

    Nature

    (1980)
  • LambrechtG. et al.

    Sci. Suppl.

    (1989)
  • Cited by (85)

    • Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders

      2019, Advances in Pharmacology
      Citation Excerpt :

      Binding studies using postmortem brain tissues from individuals with schizophrenia have also been used to assess alterations in the expression of different mAChRs, specifically M1 and/or M4. These studies were conducted by measuring changes in the binding of the M1-preferring orthosteric antagonist [3H]pirenzepine (relative binding affinity M1 > M4 > M2,3,5), under low doses thought to confer M1 specificity (Bolden, Cusack, & Richelson, 1992; Giachetti, Giraldo, Ladinsky, & Montagna, 1986; Moriya et al., 1999; Zang & Creese, 1997). In patients with schizophrenia compared to age-matched controls, these postmortem binding studies showed decreased levels of M1 in the prefrontal cortex (PFC), caudate putamen, hippocampus, and superior temporal gyrus (Crook et al.,1999; Crook, Tomaskovic-Crook, Copolov, & Dean, 2000, 2001; Dean et al., 1996; Dean, McLeod, Keriakous, McKenzie, & Scarr, 2002; Deng & Huang, 2005; Zavitsanou, Katsifis, Mattner, & Xu-Feng, 2004).

    View all citing articles on Scopus
    View full text